Find a Medicare Part D prescription drug plan for 2027

Find a Medicare Part D prescription drug plan for 2027
Reviewed by Russell Noga, Licensed Medicare Insurance Broker (all 50 states) — Last updated November 1, 2026
Farxiga can be covered by Medicare Part D in 2027, and for the first time many plans may also list generic dapagliflozin, which the FDA approved in April 2026. Brand Farxiga keeps its Medicare-negotiated price of $178.50 for a 30-day supply, while the generic could cost less depending on the plan’s tier and the pharmacy.
2027 by the Numbers
$178.50
Medicare-negotiated price, 30-day Farxiga supply, since Jan 1, 2026 (CMS)
68%
cut from the $556 list price in 2023, the deepest among the SGLT2 drugs negotiated (CMS)
April 7, 2026
FDA approval date of the first generic dapagliflozin tablets (FDA)
Farxiga (dapagliflozin) is AstraZeneca’s once-daily SGLT2 inhibitor. It is used to manage blood sugar in type 2 diabetes and is also approved for heart failure and chronic kidney disease. It was among the first 10 drugs to get a Medicare-negotiated price.
Two things are different heading into 2027. The standard Part D benefit has a higher deductible and cap, and a lower-cost generic of the same ingredient is now approved. This page looks at how both changes play out, with our own cost math for brand and generic. The full set of 2027 rules lives on the Medicare Part D plans 2027 hub.
Key Takeaways
Brand Farxiga
Negotiated Medicare price of $178.50 per 30 days
Label covers diabetes, heart failure and chronic kidney disease
Often on a brand tier, which may sit behind the deductible
Generic dapagliflozin
First approved April 7, 2026, from several makers
Initial approvals were reported for blood sugar control and lowering heart failure hospital risk in type 2 diabetes
Plans may place it on a generic tier, depending on the plan
Label detail to ask about: Generic labels can leave out some brand uses for patent reasons. If you take Farxiga for heart failure or kidney disease without diabetes, ask your pharmacist and prescriber whether the generic is appropriate and how your plan handles substitution.
We ran three versions of 2027 using the CMS standard benefit: $700 deductible, then 25% coinsurance, capped at $2,400. The generic price below is a clearly labeled assumption, not a quoted price.
| Option | How the money flows | 2027 total |
|---|---|---|
| Brand Farxiga at $178.50 | Full price January to March, $168 in April, then $44.63 a month | About $1,061 |
| Generic at an assumed $50 a month, deductible applies | Full $50 each month, deductible never fully met | About $600 |
| Generic at an assumed $10 tier copay, no deductible on generics | $10 each month | About $120 |
Illustrative math. Real generic prices differ by pharmacy and plan; some plans waive the deductible for low-cost tiers. Premiums are not included.
$996.75
brand Farxiga alone, same math under 2026 rules
$1,060.50
brand Farxiga alone under 2027 rules
+$63.75
change caused by the higher deductible
Brand Farxiga’s FDA-approved uses
Improving blood sugar in adults and children 10 and older with type 2 diabetes
Lowering the risk of heart failure hospital stays in adults with type 2 diabetes and heart disease or several heart risk factors
Lowering the risk of cardiovascular death and hospital stays in adults with heart failure
Slowing kidney decline in adults with chronic kidney disease at risk of progression
Each use is medically accepted, so a Part D plan may cover Farxiga for any of them. Prior authorization, if the plan uses it, usually asks for the diagnosis.
Advertisement
Selection rule. Medicare negotiation targets brand drugs without generic competition.
Generic arrives. Generic dapagliflozin approvals came in April 2026.
CMS review. Under program rules, CMS can remove a drug from negotiation after it finds a generic is being marketed in a real way.
Timing. Any removal takes effect after a delay set by law, so the $178.50 price is expected to apply through 2027 unless CMS announces otherwise.
The wider program, including the 15 drugs whose prices begin in 2027, is explained on our Medicare negotiated drug prices 2027 page.
| Product | Ingredients | Uses the $178.50 price? |
|---|---|---|
| Farxiga | dapagliflozin | Yes |
| Generic dapagliflozin | dapagliflozin | No; priced by the plan and pharmacy |
| Xigduo XR | dapagliflozin and metformin | No; separate product |
Fixed-dose combinations are treated as separate drugs in the negotiation program. Availability of each product can vary.
If you take a combination pill, ask whether two separate tablets would cost less on your 2027 plan, and only switch with your prescriber’s approval.
Begin Choosing your plan
Advertisement
CALL TO SPEAK WITH A LICENSED INSURANCE AGENT
Advertisement
Farxiga is often taken alongside a blood thinner. Using CMS-negotiated prices for Farxiga ($178.50) and Eliquis ($231), our standard-benefit math puts the pair at $409.50 a month in drug costs and about $1,754 for 2027, still below the cap.
Cap check: Adding a third brand drug that costs a few hundred dollars a month could push the yearly total to $2,400, after which covered drugs cost $0 for the rest of 2027. Our out-of-pocket maximum 2027 page explains what counts.
Look for these answers in each plan’s materials
Is brand Farxiga on the 2027 list, and is generic dapagliflozin listed too
Which tier each one sits on and whether the deductible applies
Whether the plan requires the generic first
Preferred pharmacy and 90-day mail-order prices
Total yearly cost with every drug you take
Not all plans cover every drug, and formularies change each January. Our Medicare Part D formulary 2027 guide shows how to read a drug list and request an exception.
The Bottom Line
Farxiga stays coverable under Part D in 2027 at its $178.50 negotiated price, and generic dapagliflozin gives many members a possible lower-cost path. In our math, brand Farxiga alone comes to about $1,061 for the year, while a generic on a low tier could cost a fraction of that. Confirm the tier, the generic’s label and your prescriber’s view before switching.
We do not offer every plan available in your area. Any information we provide is limited to those plans we do offer in your area. Please contact Medicare.gov or 1-800-MEDICARE (TTY 1-877-486-2048) to get information on all of your options.
Part D plans may add generic dapagliflozin to their 2027 formularies, depending on the plan. Check each plan’s drug list, since coverage and tier vary.
Pharmacies often substitute approved generics, and plans may favor them. Your prescriber can write for the brand if it is medically needed, and you can ask for an exception.
Yes, its $178.50 negotiated price is expected to continue in 2027. Program rules allow CMS to remove a drug later once a generic is genuinely marketed.
The negotiated price is unchanged, but the standard deductible rises to $700. In our math, that adds about $64 for someone who takes only Farxiga.
Ask your prescriber. Early generic approvals were described with diabetes-related uses, and doctors may still prescribe generics for other medically accepted uses.
No. Xigduo XR combines dapagliflozin with metformin and is a separate product, so its price is set through the plan.
Medicare Advantage plans with drug coverage can cover Farxiga and follow the same Part D rules, including the $2,400 limit.
Yes. People who qualify pay small fixed copays for covered generic and brand drugs and have no deductible.
ZRN Health & Financial Services, LLC, a Texas limited liability company.
Begin Choosing your plan
Advertisement
CALL TO SPEAK WITH A LICENSED INSURANCE AGENT
Advertisement